| 前收市價 | 526.70 |
| 開市 | 539.50 |
| 買盤 | 520.00 |
| 賣出價 | 529.00 |
| 拍板 | 360.00 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 526.70 - 539.50 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 101 |
BenzingaEli Lilly's Zepbound For Weight Loss Shows Disease Resolution In Obese Sleep Apnea Patients, Lays Further Groundwork For Label Expansion
On Friday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SURMOUNT-OSA phase 3 trials evaluating tirzepatide injection (10 mg or 15 mg) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy. In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacy and treatment-regimen estimands and demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI)
Investor's Business DailyHow To Invest After A Follow-Through Day
After last week's follow-through day, investors should be looking for top stocks breaking out past new buy points.
Barrons.comResMed Stock Is Sinking. Blame Lilly’s Zepbound Trials for Sleep Apnea.
Eli Lilly is seeking FDA approval to expand the uses for its weight-loss drug Zepbound to include sleep apnea.
